Department of Pharmacy, the First Affiliated Hospital of Third Military Medical University (Army Medical University), Chongqing, China.
Department of Respiratory Disease, the First Affiliated Hospital of Third Military Medical University (Army Medical University), Chongqing, China.
Clin Respir J. 2020 Sep;14(9):839-848. doi: 10.1111/crj.13216. Epub 2020 Jul 8.
Bronchiectasis is a common condition and a leading cause of respiratory morbidity and mortality. The treatment method for bronchiectasis is mainly symptomatic treatment or surgery; however, this condition is extremely prone to recurrence.
To preliminarily evaluate the safety and efficacy of applying SOX9 autologous airway basal cells (BCs) in patients with bronchiectasis.
SOX9 BCs were isolated from microscale tissue of a grade 3-5 bronchus by bronchoscopic brushing and expanded in vitro for approximately 4 weeks. Subsequently, the autologous SOX9 BCs were transplanted into the diseased bronchus to treat patients with bronchiectasis.
The forced expiratory volume in1 second (FEV1)%, forced vital capacity (FVC)%, total lung capacity (TLC)%, residual volume (RV)% and RV/TLC ratio of predicted value in patients with bronchiectasis were improved at 4, 12, 24 and 48 weeks after cell transplantation, although the differences were not statistically significant (P > .05). Chest CT scans showed that the lesions in the pulmonary segment had not progressed at 4, 12 and 24 weeks after transplantation. No patients died during the follow-up. At 4, 12 and 24 weeks after transplantation, routine blood tests, liver function tests, renal function tests and myocardial enzymatic indexes were normal (P > .05).
Transplantation of autologous SOX9 BCs has positive effects and is safe for patients with bronchiectasis.
支气管扩张症是一种常见疾病，也是导致呼吸道发病率和死亡率的主要原因。支气管扩张症的治疗方法主要是对症治疗或手术，但这种疾病极易复发。
初步评估 SOX9 自体气道基底层细胞（BCs）在支气管扩张症患者中的安全性和疗效。
通过支气管镜刷检从小支气管 3-5 级组织中分离 SOX9 BCs，并在体外扩增约 4 周。然后，将自体 SOX9 BCs 移植到患病支气管中，以治疗支气管扩张症患者。
支气管扩张症患者在细胞移植后 4、12、24 和 48 周时，用力呼气量（FEV1）%、用力肺活量（FVC）%、总肺活量（TLC）%、残气量（RV）%和 RV/TLC 比值与预计值相比有所改善，但差异无统计学意义（P>.05）。胸部 CT 扫描显示，在移植后 4、12 和 24 周时，肺段病变没有进展。在随访期间，没有患者死亡。在移植后 4、12 和 24 周时，常规血液检查、肝功能检查、肾功能检查和心肌酶指标均正常（P>.05）。
自体 SOX9 BCs 移植对支气管扩张症患者具有积极作用，且安全。
